Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 a...
Guardado en:
Autores principales: | Jaclyn Flanigan, Hari Deshpande, Scott Gettinger |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf568a52e46640e89d9b6362ec98daa2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of vandetanib in the management of medullary thyroid cancer
por: Rondeau G, et al.
Publicado: (2012) -
Oligometastatic non-small-cell lung cancer: current treatment strategies
por: Richard PJ, et al.
Publicado: (2016) -
Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Jade Cury-Martins, et al.
Publicado: (2018) -
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014) -
A secondary RET mutation in the activation loop conferring resistance to vandetanib
por: Takashi Nakaoku, et al.
Publicado: (2018)